VKH
MCRB icon

Virtu KCG Holdings’s Seres Therapeutics MCRB Stock Holding History

Virtu KCG Holdings’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,136
Closed -$279K – 3644
2016
Q3 		$279K Buy
+1,136
New +$399K 0.01% 1992

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Virtu KCG Holdings's MCRB Position: Q4 2016 in Review

Virtu KCG Holdings sold out of Seres Therapeutics (MCRB) in Q4 2016, closing a stake of 1,136 shares — an estimated $279K sold.

Virtu KCG Holdings first reported a position in MCRB in Q3 2016 and held it in 1 quarter. The position peaked at $279K in Q3 2016. 89 funds tracked by Wall St. Rank hold MCRB as of Q4 2016.

  • Virtu KCG Holdings reported no remaining Seres Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 1,136 Seres Therapeutics shares in Q4 2016, an estimated $279K.
  • Virtu KCG Holdings first reported a position in Seres Therapeutics in Q3 2016 and held it in 1 quarter.
  • Virtu KCG Holdings's Seres Therapeutics position peaked at $279K in Q3 2016.
  • 89 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.